Introduction {#s1}
============

Impaired renal function has been established as a significant and independent predictor of adverse cardiovascular events among patients admitted for ST- segment elevation myocardial infarction (STEMI) receiving percutaneous coronary intervention (PCI) \[[@R01]\]. There have been limited studies that investigated the role of admission serum creatinine (SCr) on major adverse clinical events in patients with STEMI. Three recent studies have demonstrated a positive correlation between decreased eGFR and increased risk of atherosclerosis and reduced left ventricular ejection fraction (EF) in acute coronary syndrome \[[@R02]-[@R04]\]. These studies found that patients with eGFR \< 60 mL/min/1.73 m^2^ had a 7.78-fold higher mortality as compared to patients with an eGFR \> 60 mL/min/1.73 m^2^ \[[@R02]-[@R04]\]. Here we investigate the impact of admission SCr on major adverse cardiovascular outcomes among STEMI patients undergoing PCI.

Patients and Methods {#s2}
====================

A retrospective study of patients, who were admitted for STEMI between January 2011 and September 2015 and have undergone primary PCI, was conducted using the National Cardiovascular Database Action Registry (NCDR) at Cleveland Clinic Akron General (CCAG) hospital. The study was approved by Institutional Review Board (IRB). The American College of Cardiology Foundation/American Heart Association (ACCF/AHA) guideline was used to define STEMI. Data elements include demographics, detailed medical history, medications, SCr at admission, and clinical outcomes during hospital stay. The primary outcome was a composite of major clinical events (cardiogenic shock, atrial fibrillation, ventricular fibrillation, ventricular tachycardia, heart failure, bleeding, and mechanical ventilation). Creatinine was the independent variable. Using below mentioned Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation, SCr (mg/dL) based estimated glomerular filtration rate (eGFR) was calculated. Patient weight is not needed for CKD-EPI equation as the results are normalized to accepted average adult body surface area of 1.73 m^2^ and the use of this equation is advocated if eGFR is \> 60 mL/min/1.73 m^2^ is desired \[[@R05]\].

GFR = 141 × min (S~cr~/κ, 1)^α^ × max (S~cr~/κ, 1)^-1.209^ × 0.993^age^ × 1.018 (if female) × 1.159 (if black)

S~cr~: serum creatinine (mg/dL); κ: 0.7 for females and 0.9 for males; α: -0.329 for females and -0.411 for males; min: minimum of S~cr~/κ or 1; max: maximum of S~cr~/κ or 1

SPSS software was used to calculate descriptive statistics and perform multivariate analysis. Categorical variables were compared using chi-square test and the differences between the observed means in the two groups were calculated using two-sample *t*-test.

Results {#s3}
=======

A total of 656 patients admitted to CCAG hospital between January 2011 and September 2015 with the diagnosis of STEMI who subsequently underwent primary PCI, were included in the study. The electrocardiograms (EKGs) were reviewed by experienced cardiologists at CCAG. All coronary angiographies and primary PCIs were performed via the femoral and radial approach. Certain medications, e.g. aspirin, clopidogrel, rosuvastatin or atorvastatin, angiotensin converting enzyme inhibitor or angiotensin receptor blocker and beta-blockers were administered as per the standard guidelines and according to the hemodynamic status of the patients. Glycoprotein IIb/IIIa receptor blockers (e.g. tirofiban) were also used based on visualized thrombus burden. Patients with abnormal SCr at admission (≥ 1.2 mg/dL) were generally older (mean age 66.84 ± 13.66 vs. 59.45 ± 11.70, P ≤ 0.0001). A significantly high percentage of the study population had prior history of hypertension(P ≤ 0.005), dyslipidemia (P ≤ 0.0005), myocardial infarction (P \< 0.005), heart failure (P ≤ 0.05) and/or cerebrovascular diseases (P ≤ 0.0005). Interestingly there was lesser number of patients with smoking history in abnormal SCr group (35.81% vs. 52.75%, P ≤ 0.0005). Patients with eGFR CKD-EPI stage III (\< 60 mL/min/1.73 m^2^) on admission had an increased incidence of cardiogenic shock (P = 0.001), bleeding (P \< 0.001), heart failure (P \< 0.0005) and higher mortality rates (P = 0.0005) ([Tables 1](#T1){ref-type="table"}, [2](#T2){ref-type="table"}). Furthermore, in the setting of STEMI, elevated SCr was associated with an increased risk of developing major adverse events like cardiogenic shock (P = 0.05), bleeding (P = 0.05), heart failure (P = 0.005). Patients with eGFR stage III (\< 60 mL/min/1.73 m^2^) had higher levels of cardiac enzymes (mean peak troponin level 92.50 ± 74.65 vs. 69.40 ± 65.51, P = 0.001). Of note, there was no significant mortality difference between abnormal and normal SCr groups (P = 0.5055). In addition, there was no statistically significant difference in the occurrence of adverse events like atrial fibrillation (P = 0.985, P = 0.296), ventricular tachycardia/ventricular fibrillation (P = 0.590, P = 0.379) and cerebrovascular accidents (CVAs) (P = 0.882, P = 0.251) between abnormal SCr and lower eGFR (\< 60 mL/min/1.73 m^2^) groups compared to normal SCr (\< 1.2 mg/dL) and higher eGFR (≥ 60 mL/min/1.73 m^2^) groups respectively.

###### Demographics and Clinical Characteristics of Patients

  Clinical characteristics                 SCr ≥ 1.2 (n = 148)   SCr \< 1.2 (n = 508)   P value
  ---------------------------------------- --------------------- ---------------------- -----------
  Age (years) (mean ± SD)                  66.84 ± 13.66         59.45 ± 11.70          \< 0.0001
  Sex male (%)                             81.76 (n = 121)       69.69 (n = 354)        
  BMI (mean ± SD)                          28.51 ± 5.55          29.54 ± 6.42           0.08
  Caucasian race (%)                       89.19 (n = 132)       88.5 (n = 450)         0.82
  African American race (%)                9.46 (n = 14)         10.24 (n = 52)         0.78
  Hispanic race (%)                        0 (n = 0)             0.20 (n = 1)           0.59
  Other race (%)                           0.68 (n = 1)          0.79 (n = 4)           
  Unkown race (%)                          0.68 (n = 1)          0.20 (n = 1)           
  Initial creatinine (mg/dL) (mean ± SD)   1.82 ± 1.88           0.89 ± 0.16            \< 0.0001
  eGFR (mL/min/1.73 m^2^) (mean ± SD)      48.36 ± 16.08         87.37 ± 16.53          \<0.0001
  Initial troponin                         4.79 ± 13.05          4.67 ± 19.53           0.944
  Peak troponin                            83.1 ± 71.29          71.22 ± 66.78          0.0612
  Hx of hypertension (%)                   74.32 (n = 110)       59.64 (n = 303)        \< 0.005
  Hx of smoker (%)                         35.81 (n = 53)        52.75 (n = 268)        \< 0.0005
  Current heart failure (%)                4.05 (n = 6)          2.75 (n = 14)          0.42
  Hx of dyslipidemia (%)                   64.86 (n = 96)        47.63 (n = 242)        \< 0.0005
  Hx of chronic lung disease (%)           10.13 (n = 15)        7.08 (n = 36)          0.22
  Hx of diabetes (%)                       22.97 (n = 34)        18.5 (n = 97)          0.23
  Hx of prior MI (%)                       29.72 (n = 44)        18.3 (n = 93)          \< 0.005
  Hx of prior heart failure (%)            8.78 (n = 13)         3.74 (n = 19)          \< 0.05
  Hx of A fib/A flutter (%)                3.37 (n = 5)          1.18 (n = 6)           0.07
  Hx of prior PCI (%)                      27.7 (n = 41)         17.51 (n = 89)         \< 0.01
  Hx of prior CABG (%)                     13.51 (n = 20)        6.88 (n = 35)          \< 0.05
  Hx of cerebrovascular stroke (%)         8.1 (n = 12)          3.74 (n = 19)          \< 0.05
  Hx of cerebrovascular disease (%)        15.54 (n = 23)        5.51 (n = 28)          \< 0.0005
  Hx of peripheral arterial disease (%)    14.18 (n = 21)        5.7 (n = 29)           \< 0.001
  Hx of current dialysis (%)               2.02 (n = 3)          0 (n = 0)              
  Hx of cerebrovascular TIA (%)            3.38 (n = 5)          0.79 (n = 4)           \< 0.05

Scr: serum creatinine at admission; BMI: body mass index; eGFR: estimated glomerular filtration rate; Hx: history; MI: myocardial infarction; PCI: percutaneous coronary intervention; CABG: coronary artery bypass grafting; TIA: transient ischemic attack; A fib: atrial fibrillation; A flutter: atrial flutter.

###### Adverse Clinical Outcomes Based on Admission Serum Creatinine and eGFR

  Adverse outcomes             SCr ≥ 1.2 (n = 148)   SCr \< 1.2 (n = 508)   P value    eGFR ≥ 60 (n = 527)   eGFR \< 60 (n = 129)   P value
  ---------------------------- --------------------- ---------------------- ---------- --------------------- ---------------------- -----------
  Initial troponin                                                                     4.52 ± 19.23          5.40 ± 13.61           0.624
  Peak troponin                                                                        69.40 ± 65.51         92.50 ± 74.65          \< 0.001
  Atrial fibrillation (%)      1.35 (n = 2)          1.37 (n = 7)           0.9853     1.13 (n = 6)          2.32 (n = 3)           0.2967
  V Tach/V Fib (%)             3.37 (n = 5)          2.55 (n = 13)          0.5907     2.46 (n = 13)         3.87 (n = 5)           0.3794
  New dialysis (%)             0 (n = 0)             0.39 (n = 2)           0.4471     0.37 (n = 2)          0 (n = 0)              0.4893
  Mechanical ventilation (%)   0.67 (n = 1)          0.78 (n = 4)           0.8919     0.75 (n = 4)          0.77 (n = 1)           0.9812
  Cardiogenic shock (%)        11.48 (n = 17)        6.29 (n = 32)          \< 0.05    5.69 (n = 30)         14.72 (n = 19)         \< 0.001
  Heart failure (%)            15.54 (n = 23)        6.69 (n = 34)          \< 0.005   6.45 (n = 34)         17.82 (n = 23)         \< 0.0005
  Bleeding (%)                 8.78 (n = 13)         3.93 (n = 20)          \< 0.05    3.6 (n = 19)          10.85 (n = 14)         \< 0.001
  CVA (%)                      0.67 (n = 1)          0.79 (n = 4)           0.8827     0.57 (n = 3)          1.55 (n = 2)           0.2519
  Mortality (%)                6.08 (n = 9)          4.72 (n = 7)           0.5055     1.33 (n = 7)          6.98 (n = 9)           \< 0.0005

SCr: serum creatinine at admission; V Tach: ventricular tachycardia; V Fib: ventricular fibrillation; CVA: cerebrovascular accident; eGFR: estimated glomerular filtration rate at admission.

Discussion {#s4}
==========

Chronic kidney disease (CKD) is associated with arrhythmias, cardiomyopathy (dilated and hypertrophic variant), left ventricular (LV) hypertrophy and dysfunction, increased carotid intima-medial thickness (IMT), endothelial dysfunction (as measured by flow mediated dilation of the brachial artery), and calcification of the coronaries. These constitute independent predictors of cardiac morbidity and mortality \[[@R06]\]. CKD and uremia-induced decreased shortening at the myocardial mid-wall result in low contractile reserve during stress. This causes reduced global and segmental myocardial blood flow, leading to myocardial stunning \[[@R06]\].

In this study, patients with STEMI who had elevated admission SCr and eGFR \< 60 mL/min/1.73 m^2^ showed an increased risk of developing major adverse clinical events including cardiogenic shock, bleeding and heart failure. In addition, mortality rates were significantly higher in patients with eGFR \< 60 mL/min/1.73 m^2^. Cardiovascular morbidity and mortality is evident in early renal disease and in patients with CKD because of hemodynamic overload and several metabolic and endocrine imbalances that are fairly specific to uremia \[[@R07]\]. Furthermore, renal failure is associated with a pro-coagulant state, higher homocysteine levels, and endothelial dysfunction that promote atherosclerosis and plaque formation \[[@R08], [@R9]\]. CKD with NSTEMI is associated with increased risk of in-hospital adverse events, which are complicated with longer hospital stay and higher medical costs \[[@R04]\]. In another study, longer hospital stay was observed in the lowest eGFR group due to increased in-hospital adverse events \[[@R10]\]. Studies have also shown that the risk of stroke increases with renal dysfunction \[[@R10], [@R11]\]. However, our study did not show any difference in cerebrovascular accident rates between patients with normal and abnormal renal functions.

Regarding the classification of CKD, CKD-EPI correlated with MDRD and Cockcroft and Gault (CG) formula 92% of the time \[[@R12]\]. All three definitions correlate well with outcomes; however CKD-EPI predicts worse prognosis better than MDRD or CG in STEMI patients \[[@R12]\]. The limitations of calculating renal functions from SCr alone or from a 24 h urine creatinine clearance, and the cost and complexities involved in measuring endogenous eGFR or determining inulin/radionuclide based gold standard GFR lead to eGFR calculation \[[@R12]\]. Authors feel the CKD-EPI equation includes log SCr (modeled as a two-slope linear spline with sex specific knots at 62 µmol/L in women and 80 µmol/L in men), with gender, race and age on the natural scale. It is therefore effectively four different equations for Caucasians (men, women, above the knot value, below the knot value) and another four for African-Americans in whom a different factor is used considerably outweighing their reliability and making them unsuitable for routine use in the patients with STEMI \[[@R12]\]. Regardless of definition, increased admission SCr corresponded with increased risk of major adverse cardiovascular outcomes among STEMI patients undergoing PCI. However, in our study, except for cardiogenic shock, bleeding and heart failure, there was no significant difference in the occurrence of atrial fibrillation, ventricular tachycardia/ventricular fibrillation and CVAs between elevated SCr and lower eGFR (\< 60 mL/min/1.73 m^2^) groups compared to normal SCr (\< 1.2 mg/dL) and higher eGFR (≥ 60 mL/min/1.73 m^2^) groups respectively.

Our study also showed higher percentage of patients with common comorbidities (hypertension, diabetes, and dyslipidemia) and prior history of myocardial infarction, heart failure and cerebrovascular disease among elevated SCr group. These patients were also commonly male with an older age. These clinical factors are associated with poor prognosis in the setting of acute myocardial infarction. Multivariate regression analysis showed mild deterioration of eGFR (derived per CKD-EPI) was prognostic in STEMI patients undergoing primary PCI. Our cohort with CKD stage III or greater was associated with higher rates of decreased left ventricular function, higher troponins levels and increased mortality rates. This study was in accordance with Sonmez et al who showed that an eGFR \< 60 mL/min/1.73 m^2^ was associated with reduced left ventricular ejection fraction and larger myocardial infarct size in patients undergoing primary PCI for STEMI \[[@R13]\].

Use of a standardized, evidence-based approach involving careful evaluation of GFR on admission for STEMI patients undergoing PCI is essential. Early recognition of patients at risk for development of AKI/CKD post-PCI is paramount to improve the outcomes of an otherwise life-saving therapy. These findings emphasize the importance of a multidisciplinary approach involving nephrologists and interventionists for early recognition and management of AKI/CKD in patients with STEMI undergoing PCI. Future large-scale prospective studies are needed to confirm our findings. Additionally, CKD-EPI derived eGFR should be used for prediction of in-hospital and long-term mortality in STEMI patients undergoing primary PCI.

Conclusions {#s4a}
-----------

In the setting of STEMI, elevated SCr and eGFR \< 60 mL/min/1.73 m^2^ were associated with an increased risk of developing major adverse clinical events including cardiogenic shock, bleeding and heart failure in patients undergoing PCI. In-hospital adverse events are complicated by longer hospital stay and higher medical costs; therefore it is imperative to identify those at greater risk earlier in their clinical course. Our findings need to be validated in a larger group and multi-center registry for a better understanding of eGFR and adverse outcomes after PCI following STEMI.
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